Pharmaceuticals in New Zealand

Pharmaceuticals in New Zealand


November 21, 2012
34 Pages - SKU: MTLN4921233
License type:
Online Download      US $350.00
Global Site License      US $875.00
Countries covered: New Zealand

Introduction

Pharmaceuticals in New Zealand industry profile provides top-line qualitative and quantitative summary information including: market size (value 2007-11, and forecast to 2016). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the New Zealand pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights
  • The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
  • The New Zealand pharmaceuticals market had total revenues of $931.1 million in 2011, representing a compound annual growth rate (CAGR) of 2.9% between 2007 and 2011.
  • The performance of the market is forecast to decelerate, with an anticipated CAGR of 1.9% for the five-year period 2011 - 2016, which is expected to drive the market to a value of $1 billion by the end of 2016.
Features

Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in New Zealand

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in New Zealand

Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the New Zealand pharmaceuticals market with five year forecasts

Macroeconomic indicators provide insight into general trends within the New Zealand economy

Key Questions Answered

What was the size of the New Zealand pharmaceuticals market by value in 2011?

What will be the size of the New Zealand pharmaceuticals market in 2016?

What factors are affecting the strength of competition in the New Zealand pharmaceuticals market?

How has the market performed over the last five years?



More Manufacturing, Packaging & Detailing reports by MarketLine

Orphan Drugs: Rescue from the patent cliff by MarketLine
IntroductionOrphan drugs treat diseases that affect fewer than 1 in 2,000 Europeans & fewer than 200,000 Americans. Research into orphan drugs benefits from incentives provided ...
Pharmaceuticals: Global Industry Guide by MarketLine
Pharmaceuticals: Global Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals: Global Industry Guide industry. It includes detailed data on ...
Pharmaceuticals - North America (NAFTA) Industry Guide by MarketLine
Pharmaceuticals - North America (NAFTA) Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the North ...
Pharmaceuticals - Global Group of Eight (G8) Industry Guide by MarketLine
Pharmaceuticals - Global Group of Eight (G8) Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of ...
See all reports like this >>

More New Zealand Manufacturing, Packaging & Detailing reports

New Zealand Pharmaceuticals and Healthcare Report Q2 2014 by Business Monitor International
New Zealand Pharmaceuticals and Healthcare Report Q2 2014BMI View: We highlight that the attractiveness of New Zealand's pharmaceutical market is highlydependent on the decisions made ...
Healthcare, Regulatory and Reimbursement Landscape - New Zealand by GlobalData
Healthcare, Regulatory and Reimbursement Landscape - New Zealand Summary GlobalData, the industry analysis specialist, has released its new report, “Healthcare, Regulatory and Reimbursement ...
New Zealand Pharmaceuticals and Healthcare Report Q1 2013 by Business Monitor International
BMI View: Low growth potential in New Zealand's pharmaceutical market will attract risk-averseinvestors. However, we note that regulatory delays in funding new medicines will hinder ...
New Zealand Pharmaceuticals and Healthcare Report Q4 2012 by Business Monitor International
BMI View: Strained public finances and a resultant focus on cost containment is expected to feed through into weak growth for New Zealand’s pharmaceutical market. ...
See all reports like this >>

More New Zealand reports

D&B Country RiskLine Report: New Zealand by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: New Zealand by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
See all reports like this >>